SFMBT2

Summary

SFMBT2 (Scm like with four mbt domains 2, HGNC:20256) is a protein-coding gene on chromosome 10p14, encoding Scm-like with four MBT domains protein 2 (Q5VUG0). Transcriptional repressor of HOXB13 gene.

Enables histone binding activity. Involved in negative regulation of gene expression. Located in aggresome; cytosol; and nuclear speck.

Source: NCBI Gene 57713 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 149 total
• MANE Select transcript: NM_001387889

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20256
Approved symbol	SFMBT2
Name	Scm like with four mbt domains 2
Location	10p14
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1617
Ensembl gene	ENSG00000198879
Ensembl biotype	protein_coding
OMIM	615392
Entrez	57713

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 8 protein_coding, 2 nonsense_mediated_decay, 1 retained_intron

ENST00000361972, ENST00000379711, ENST00000379713, ENST00000397167, ENST00000673876, ENST00000682043, ENST00000682101, ENST00000682180, ENST00000682896, ENST00000683762, ENST00000684547

RefSeq mRNA: 5 — MANE Select: NM_001387889 NM_001018039, NM_001029880, NM_001387889, NM_001387890, NM_001387891

CCDS: CCDS31138

Canonical transcript exons

ENST00000397167 — 21 exons

Exon	Start	End
ENSE00000689524	7248548	7248649
ENSE00000837270	7227855	7227937
ENSE00000837272	7276892	7276989
ENSE00000837273	7283904	7284150
ENSE00000915092	7220411	7220537
ENSE00000915093	7243558	7243705
ENSE00000915094	7367649	7367889
ENSE00000915095	7370281	7370375
ENSE00000985193	7205815	7205928
ENSE00000985194	7202480	7202522
ENSE00000985195	7200414	7200484
ENSE00000985196	7197548	7197687
ENSE00000985197	7188624	7188733
ENSE00000985198	7175990	7176165
ENSE00000985199	7172495	7172661
ENSE00000985200	7171895	7172158
ENSE00000985201	7170928	7171056
ENSE00001215170	7285866	7285954
ENSE00001215204	7381799	7381949
ENSE00001629306	7158624	7163910
ENSE00003921905	7410861	7411034

Expression profiles

Bgee: expression breadth ubiquitous, 230 present calls, max score 85.93.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.9047 / max 217.7955, expressed in 1019 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
108184	5.6412	1017
108185	0.2635	115

Top tissues by expression

247 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	85.93	gold quality
bone marrow cell	CL:0002092	85.79	gold quality
cartilage tissue	UBERON:0002418	83.13	gold quality
corpus callosum	UBERON:0002336	81.56	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.50	gold quality
decidua	UBERON:0002450	79.56	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	79.41	gold quality
adrenal tissue	UBERON:0018303	79.14	gold quality
granulocyte	CL:0000094	79.00	gold quality
mucosa of stomach	UBERON:0001199	78.45	gold quality
spleen	UBERON:0002106	78.32	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	77.57	gold quality
colonic epithelium	UBERON:0000397	77.30	gold quality
leukocyte	CL:0000738	77.17	gold quality
spinal cord	UBERON:0002240	77.15	gold quality
lymph node	UBERON:0000029	77.04	gold quality
monocyte	CL:0000576	76.87	gold quality
left ovary	UBERON:0002119	76.75	gold quality
Brodmann (1909) area 46	UBERON:0006483	76.73	gold quality
vermiform appendix	UBERON:0001154	75.67	gold quality
ovary	UBERON:0000992	75.61	gold quality
lower esophagus muscularis layer	UBERON:0035833	75.58	gold quality
prostate gland	UBERON:0002367	75.51	gold quality
lower esophagus	UBERON:0013473	75.51	gold quality
right ovary	UBERON:0002118	75.25	gold quality
hypothalamus	UBERON:0001898	74.94	gold quality
superficial temporal artery	UBERON:0001614	74.89	gold quality
epithelium of nasopharynx	UBERON:0001951	74.80	silver quality
tibialis anterior	UBERON:0001385	74.52	silver quality
bone marrow	UBERON:0002371	74.41	gold quality

Single-cell (SCXA)

Detected in 7 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-GEOD-100618	yes	238.18
E-MTAB-9067	yes	194.94
E-HCAD-35	yes	41.03
E-CURD-119	yes	27.19
E-HCAD-25	yes	21.71
E-ANND-3	yes	5.05
E-CURD-10	no	58.76

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

147 targeting SFMBT2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4715-3P	99.98	66.03	670
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-7152-3P	99.97	67.47	849
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-3671	99.90	73.04	3897

Literature-anchored findings (GeneRIF, showing 9)

• SFMBT2 may regulate cell growth via epigenetic regulation of HOXB13 gene expression in prostate cancer cells. (PMID:23385818)
• Findings suggest that regulation of SFMBT2 may provide a new therapeutic strategy to control prostate cancer metastasis as well as being a potential biomarker of metastatic prostate cancer. (PMID:27340776)
• we revealed that SFMBT2 intervention by siRNA contributed to the catabolic phenotype of human chondrocytes mediated by NF-kB pathway. (PMID:30133133)
• The present study identified Scmlike with four malignant brain tumor domains 2 (SFMBT2) as a novel regulator of SOX9 expression. (PMID:30272322)
• Circular RNA SFMBT2 Inhibits the Proliferation and Metastasis of Glioma Cells Through Mir-182-5p/Mtss1 Pathway. (PMID:32729377)
• CircSFMBT2 facilitates vascular smooth muscle cell proliferation by targeting miR-331-3p/HDAC5. (PMID:33166591)
• Circ-SFMBT2 facilitates the malignant growth of acute myeloid leukemia cells by modulating miR-582-3p/ZBTB20 pathway. (PMID:34825699)
• [Effects of circ-SFMBT2 on Proliferation, Migration and Invasion of Acute Myeloid Leukemia Cells by Regulating miR-491-5p/HOXA9 Axis]. (PMID:38071034)
• Acetylation- and ubiquitination-regulated SFMBT2 acts as a tumor suppressor in clear cell renal cell carcinoma. (PMID:38734627)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	sfmbt2	ENSDARG00000045519
mus_musculus	Sfmbt2	ENSMUSG00000061186
rattus_norvegicus	Sfmbt2	ENSRNOG00000029235
drosophila_melanogaster	l(3)mbt	FBGN0002441
drosophila_melanogaster	Sfmbt	FBGN0032475
caenorhabditis_elegans	lin-61	WBGENE00003041
caenorhabditis_elegans	mbtr-1	WBGENE00021661

Paralogs (18): SCMH1 (ENSG00000010803), MBTD1 (ENSG00000011258), SCML1 (ENSG00000047634), L3MBTL2 (ENSG00000100395), SCML2 (ENSG00000102098), PHC1 (ENSG00000111752), THAP10 (ENSG00000129028), PHC2 (ENSG00000134686), SAMD1 (ENSG00000141858), SCML4 (ENSG00000146285), L3MBTL4 (ENSG00000154655), SFMBT1 (ENSG00000163935), PHC3 (ENSG00000173889), L3MBTL1 (ENSG00000185513), SAMD7 (ENSG00000187033), SAMD11 (ENSG00000187634), L3MBTL3 (ENSG00000198945), SAMD13 (ENSG00000203943)

Protein

Protein identifiers

Scm-like with four MBT domains protein 2 — Q5VUG0 (reviewed: Q5VUG0)

All UniProt accessions (9): Q5VUG0, A0A669KBL2, A0A804HJD5, A0A804HJE9, A0A804HK46, A0A804HKS4, A0A804HLD5, Q5T980, Q5T981

UniProt curated annotations — full annotation on UniProt →

Function. Transcriptional repressor of HOXB13 gene.

Subunit / interactions. Interacts with YY1. Interacts with methylated histones H3K9me2 and H4K20me2, but not with H3K4me2, nor H3K9Ac.

Subcellular location. Nucleus.

RefSeq proteins (5): NP_001018049, NP_001025051, NP_001374818, NP_001374819, NP_001374820 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001660	SAM	Domain
IPR004092	Mbt	Domain
IPR013761	SAM/pointed_sf	Homologous_superfamily
IPR021987	SLED	Domain
IPR037604	Scm-like-4MBT1/2_SAM	Domain
IPR038348	SLED_sf	Homologous_superfamily
IPR047353	MBT_SFMBT2_rpt1	Repeat
IPR047354	MBT_SFMBT2_rpt3	Repeat
IPR047355	MBT_SFMBT2_rpt4	Repeat
IPR050548	PcG_chromatin_remod_factors	Family

Pfam: PF00536, PF02820, PF12140

UniProt features (24 total): compositionally biased region 5, repeat 4, helix 4, strand 4, turn 2, region of interest 2, chain 1, sequence variant 1, domain 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
1WJR	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5VUG0-F1	76.55	0.50

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 187 (showing top): GTGCCTT_MIR506, THEODOROU_MAMMARY_TUMORIGENESIS, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, YAMAZAKI_TCEB3_TARGETS_UP, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, PACHER_TARGETS_OF_IGF1_AND_IGF2_UP, VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY_UP, GOMF_CHROMATIN_BINDING, GOCC_NUCLEAR_SPECK, GOCC_NUCLEAR_BODY, GOCC_RIBONUCLEOPROTEIN_GRANULE, MASSARWEH_TAMOXIFEN_RESISTANCE_UP, GOMF_HISTONE_BINDING, BOYLAN_MULTIPLE_MYELOMA_PCA3_UP, ROVERSI_GLIOMA_COPY_NUMBER_DN

GO Biological Process (3): negative regulation of gene expression (GO:0010629), negative regulation of DNA-templated transcription (GO:0045892), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (4): chromatin binding (GO:0003682), transcription corepressor activity (GO:0003714), histone binding (GO:0042393), protein binding (GO:0005515)

GO Cellular Component (6): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829), aggresome (GO:0016235), nuclear body (GO:0016604), nuclear speck (GO:0016607)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of gene expression	2
DNA-templated transcription	2
binding	2
cellular anatomical structure	2
gene expression	1
negative regulation of macromolecule biosynthetic process	1
regulation of DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
regulation of RNA biosynthetic process	1
transcription coregulator activity	1
negative regulation of DNA-templated transcription	1
protein binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cytoplasm	1
inclusion body	1
nucleoplasm	1
intracellular membraneless organelle	1
nuclear ribonucleoprotein granule	1

Protein interactions and networks

STRING

778 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SFMBT2	SLC38A4	Q969I6	717
SFMBT2	JADE1	Q6IE81	663
SFMBT2	SMOC1	Q9H4F8	628
SFMBT2	DLK1	P15803	572
SFMBT2	YY1	P25490	552
SFMBT2	H3C1	P02295	521
SFMBT2	H3-7	Q5TEC6	521
SFMBT2	H3C14	Q71DI3	520
SFMBT2	H3-5	Q6NXT2	520
SFMBT2	H3-4	Q16695	520
SFMBT2	H3-3A	P06351	518
SFMBT2	TSSC4	Q9Y5U2	518
SFMBT2	PHLDA2	Q53GA4	448
SFMBT2	IGF2R	P11717	439
SFMBT2	SNRPN	P14648	427

IntAct

41 interactions, top by confidence:

A	B	Type	Score
PHC1	CBX4	psi-mi:“MI:0914”(association)	0.790
PHC1	SFMBT2	psi-mi:“MI:0915”(physical association)	0.740
SFMBT2	SIAH1	psi-mi:“MI:0915”(physical association)	0.560
SFMBT2	UBE2O	psi-mi:“MI:0915”(physical association)	0.560
SFMBT2	SLF2	psi-mi:“MI:0915”(physical association)	0.560
SFMBT2	L3MBTL3	psi-mi:“MI:0915”(physical association)	0.560
TFAP4	SFMBT2	psi-mi:“MI:0915”(physical association)	0.560
SFMBT2	SCMH1	psi-mi:“MI:0915”(physical association)	0.560
LYPLA1	SFMBT2	psi-mi:“MI:0915”(physical association)	0.560
SFMBT2	SCML2	psi-mi:“MI:0915”(physical association)	0.560
SFMBT2	SCML1	psi-mi:“MI:0915”(physical association)	0.560
KDM1A	SFMBT2	psi-mi:“MI:0915”(physical association)	0.400
PHC1	CBX6	psi-mi:“MI:0914”(association)	0.350
SFMBT2	DCD	psi-mi:“MI:0914”(association)	0.350
KLHL22	TRAV18	psi-mi:“MI:0914”(association)	0.350
UBE2O	SFMBT2	psi-mi:“MI:0915”(physical association)	0.000
SFMBT2	SLF2	psi-mi:“MI:0915”(physical association)	0.000
SFMBT2	L3MBTL3	psi-mi:“MI:0915”(physical association)	0.000
TFAP4	SFMBT2	psi-mi:“MI:0915”(physical association)	0.000
SFMBT2	SCML1	psi-mi:“MI:0915”(physical association)	0.000
SCMH1	SFMBT2	psi-mi:“MI:0915”(physical association)	0.000
SFMBT2	PHC1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (42): SFMBT2 (Affinity Capture-RNA), SFMBT2 (Affinity Capture-RNA), SFMBT2 (Biochemical Activity), SFMBT2 (Affinity Capture-MS), SFMBT2 (Affinity Capture-RNA), SFMBT2 (Affinity Capture-RNA), SFMBT2 (Two-hybrid), SFMBT2 (Two-hybrid), SFMBT2 (Two-hybrid), SFMBT2 (Two-hybrid), SFMBT2 (Two-hybrid), SFMBT2 (Two-hybrid), SFMBT2 (Two-hybrid), SFMBT2 (Two-hybrid), SFMBT2 (Two-hybrid)

ESM2 similar proteins: A0JNA8, A2AFR3, A2AWP8, F1LXF1, O15034, O94844, O94967, O95267, P11274, P28028, Q01826, Q08BT5, Q14161, Q14CM0, Q15139, Q3UGM2, Q3UHE1, Q4R4I0, Q5R5M3, Q5VUG0, Q5XIS9, Q60611, Q62101, Q66H91, Q68FF6, Q6NZQ4, Q6PAJ1, Q6PB44, Q6ZW49, Q6ZWH5, Q80U28, Q8BWW9, Q8BZ03, Q8CGF6, Q8TCU6, Q8VDD9, Q8VI24, Q96GD3, Q9BZ71, Q9BZL6

Diamond homologs: A2A5N8, B1B1A0, D3YUG0, D3YXK1, D3ZWK4, E1C2V1, O02274, O60284, O95251, P39769, P59178, P70047, P70475, P78364, P97500, Q01538, Q05BQ5, Q1JQD9, Q1RNF8, Q29L50, Q32N90, Q3MIF2, Q4V7W5, Q5DTW2, Q5R737, Q5SVQ0, Q5VUG0, Q5VXD3, Q64028, Q6DIN3, Q6P5G3, Q6SPE9, Q6SPF0, Q7Z3H4, Q80TY4, Q810T5, Q8BLB7, Q8C8Y5, Q8CFC2, Q8CHP6

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 16 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Regulation of PTEN gene transcription	5	89.2×	8e-08

Disease & clinical

Clinical variants and AI predictions

ClinVar

149 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	123
Likely benign	8
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

5779 predictions. Top by Δscore:

Variant	Effect	Δscore
10:7163907:TATC:T	acceptor_gain	1.0000
10:7163908:ATCCT:A	acceptor_loss	1.0000
10:7163909:TC:T	acceptor_gain	1.0000
10:7163909:TCCTG:T	acceptor_loss	1.0000
10:7163910:CC:C	acceptor_gain	1.0000
10:7163910:CCTGC:C	acceptor_loss	1.0000
10:7163911:C:CA	acceptor_loss	1.0000
10:7163911:C:CC	acceptor_gain	1.0000
10:7163912:T:G	acceptor_loss	1.0000
10:7171935:T:TA	donor_gain	1.0000
10:7172155:TTTC:T	acceptor_gain	1.0000
10:7172157:TC:T	acceptor_gain	1.0000
10:7172158:CC:C	acceptor_gain	1.0000
10:7172159:C:CA	acceptor_loss	1.0000
10:7172160:T:C	acceptor_loss	1.0000
10:7172491:ATACC:A	donor_loss	1.0000
10:7172492:TACCT:T	donor_loss	1.0000
10:7172493:ACCTC:A	donor_gain	1.0000
10:7172494:C:A	donor_loss	1.0000
10:7172494:CCTCC:C	donor_gain	1.0000
10:7172496:T:TA	donor_gain	1.0000
10:7172497:C:A	donor_gain	1.0000
10:7172533:T:TA	donor_gain	1.0000
10:7172657:ATAGG:A	acceptor_gain	1.0000
10:7172658:TAGG:T	acceptor_gain	1.0000
10:7172659:AGG:A	acceptor_gain	1.0000
10:7172660:GG:G	acceptor_gain	1.0000
10:7172661:GCTG:G	acceptor_loss	1.0000
10:7172662:C:CC	acceptor_gain	1.0000
10:7172663:T:G	acceptor_loss	1.0000

AlphaMissense

5851 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:7163791:G:C	F888L	1.000
10:7163791:G:T	F888L	1.000
10:7163793:A:G	F888L	1.000
10:7163804:A:T	V884D	1.000
10:7163825:A:G	L877S	1.000
10:7163834:G:T	A874D	1.000
10:7163835:C:G	A874P	1.000
10:7163841:C:G	G872R	1.000
10:7163841:C:T	G872R	1.000
10:7163849:A:G	L869P	1.000
10:7163882:A:G	L858P	1.000
10:7163885:A:G	L857P	1.000
10:7163888:A:G	L856P	1.000
10:7163891:A:G	L855P	1.000
10:7163900:C:A	G852V	1.000
10:7163900:C:T	G852D	1.000
10:7163901:C:A	G852C	1.000
10:7163901:C:G	G852R	1.000
10:7171000:C:A	W824C	1.000
10:7171000:C:G	W824C	1.000
10:7171002:A:G	W824R	1.000
10:7171002:A:T	W824R	1.000
10:7171010:G:T	P821Q	1.000
10:7367765:C:G	R107P	1.000
10:7367811:A:G	W92R	1.000
10:7367811:A:T	W92R	1.000
10:7163796:C:G	A887P	0.999
10:7163800:T:A	K885N	0.999
10:7163800:T:G	K885N	0.999
10:7163821:G:C	C878W	0.999

dbSNP variants (sampled 300 via entrez): RS1000003150 (10:7342905 A>G), RS1000019145 (10:7377415 C>T), RS1000022720 (10:7399307 A>C,T), RS1000035936 (10:7311324 C>G), RS1000042445 (10:7249396 G>A,T), RS1000045888 (10:7225565 C>G), RS1000081700 (10:7299944 A>T), RS1000088771 (10:7189627 G>A,T), RS1000090588 (10:7160886 G>A,C), RS1000113852 (10:7270195 G>C), RS1000115108 (10:7370407 A>G), RS1000125328 (10:7267970 G>A), RS1000136377 (10:7305231 T>C), RS1000144770 (10:7302437 G>A), RS1000145567 (10:7296007 A>G)

Disease associations

OMIM: gene MIM:615392 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST001526_18	Fasting blood insulin (BMI interaction)	3.000000e-06
GCST007824_7	Monoclonal gammopathy of undetermined significance	7.000000e-06
GCST007995_29	Asthma (childhood onset)	8.000000e-14
GCST010266_8	Femoral neck bone mineral density and trunk fat mass adjusted by trunk lean mass	3.000000e-07
GCST010268_3	Femoral neck bone mineral density	6.000000e-08
GCST012490_304	Femur bone mineral density x serum urate levels interaction	9.000000e-10

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0007785	femoral neck bone mineral density
EFO:0004531	urate measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

52 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	5
trichostatin A	affects cotreatment, increases expression	3
sodium arsenite	increases abundance, decreases expression, affects cotreatment	2
entinostat	increases expression, affects cotreatment	2
belinostat	increases expression, affects cotreatment	2
Vorinostat	affects cotreatment, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Nickel	increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
bisphenol A	affects cotreatment, increases methylation	1
butyraldehyde	increases expression	1
perfluorooctanoic acid	decreases expression	1
manganese chloride	decreases expression, increases abundance, affects cotreatment	1
benzo(e)pyrene	decreases methylation	1
potassium chromate(VI)	decreases expression	1
ferrous chloride	decreases expression	1
aflatoxin B2	decreases methylation	1
pentanal	increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
perfluorohexanesulfonic acid	decreases expression	1
ormosil	affects binding, increases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	decreases expression	1
(+)-JQ1 compound	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.